Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
Learn more: Promising novel treatment against Alzheimer Disease
The Latest on: Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s
- What Is The Best Treatment for Alzheimer's?on April 26, 2024 at 9:10 pm
Alzheimerrsquo;s disease is a condition that leads to the deterioration of brain cells Read on to learn about its treatment measures ...
- Alzheimer's All-Star Basketball Classic's founder, Gordon Thomas, inspired by dad's battle with diseaseon April 26, 2024 at 11:50 am
Celeste Taylor, Lester Quinones and Diego Maldonado are just a few of the talented players who have participated in the competitions.
- Neuroscientists Warn of 'Cascading' Alzheimer's Risk From These Two Habitson April 26, 2024 at 10:37 am
The habits produce a "synergistic effect" on our risk of developing Alzheimer's Disease and general cognitive decline.
- AI helps researchers uncover gut-brain interactions in Alzheimer'son April 26, 2024 at 10:00 am
AI technology reveals more information about the gut-brain health link in Alzheimer's, suggesting new pathways for research around treatments.
- Central Pa. woman with Alzheimer’s is missing: policeon April 26, 2024 at 6:35 am
Police in Lancaster are searching for a missing 75-year-old woman with Alzheimer’s. Carlota Arauz was reported missing by her family members around 8:30 p.m. on Thursday, according to Lancaster City ...
- Sponsored: Take on Alzheimer's campaign aims to make impact with awareness and supporton April 25, 2024 at 5:28 pm
Public Health Physician Lucia Abascal joined host Jessica Wills to share how the Take on Alzheimer's campaign is helping to spread awareness and erase stigmas surrounding the disease. Watch the clips ...
- For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Doon April 25, 2024 at 8:00 am
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
- Aggressive Alzheimer's patients don't have to suffer under Medicaidon April 25, 2024 at 2:10 am
Centers for Medicare and Medicaid Services do not allow chemical restraints like sedation in any state for obvious reasons. Indiana is no exception. Aggressive individuals cannot be kept in a ...
- Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow starton April 24, 2024 at 9:15 am
Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new Alzheimer's disease drug remained sluggish. Sales of Alzheimer's drug Leqembi, ...
via Bing News